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Abstract
Background: The TTH48 trial aims to determine whether prolonged duration (48 hours) of targeted temperature
management (TTM) at 33 (±1) °C results in better neurological outcomes compared to standard duration (24 hours)
after six months in comatose out-of-hospital cardiac arrest (OHCA) patients.
Methods: TTH48 is an investigator-initiated, multicentre, assessor-blinded, randomised, controlled superiority trial of
24 and 48 hours of TTM at 33 (±1) ° C performed in 355 comatose OHCA patients aged 18 to 80 years who were
admitted to ten intensive care units (ICUs) in six Northern European countries.
The primary outcome of the study is the Cerebral Performance Category (CPC) score observed at six months after
cardiac arrest. CPC scores of 1 and 2 are defined as good neurological outcomes, and CPC scores of 3, 4 and 5 are
defined as poor neurological outcomes. The secondary outcomes are as follows: mortality within six months after
cardiac arrest, CPC at hospital discharge, Glasgow Coma Scale (GCS) score on day 4, length of stay in ICU and at
hospital and the presence of any adverse events such as cerebral, circulatory, respiratory, gastrointestinal, renal,
metabolic measures, infection or bleeding.
With the planned sample size, we have 80% power to detect a 15% improvement in good neurological outcomes
at a two-sided statistical significance level of 5%.
Discussion: We present a detailed statistical analysis protocol (SAP) that specifies how primary and secondary
outcomes should be evaluated. We also predetermine covariates for adjusted analyses and pre-specify sub-groups
for sensitivity analyses. This pre-planned SAP will reduce analysis bias and add validity to the findings of this trial on
the effect of length of TTM on important clinical outcomes after cardiac arrest.
Trial registration: ClinicalTrials.gov: NCT01689077, 17 September 2012
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Background
Time-differentiated targeted temperature management
after out-of-hospital cardiac arrest (TTH48) is an inter-
national multicentre randomised pragmatic clinical trial.
It is the first randomised trial to explore the influence of
prolonged targeted temperature management (TTM) on
neurological outcomes in out-of-hospital cardiac arrest
(OHCA) patients. In 2002 two randomized studies
demonstrated an effect on cerebral outcome of TTM at
33 °C for respectively 12 and 24 hours following OHCA.
This led to international guidelines recommendations of
the use of TTM. Animal studies have demonstrated that
cooling for periods longer than 24 hours might even add
to the beneficial effect. Furthermore in neonates it is
good clinical practice to cool patients with anoxic brain
injury for 72 hours. However we found no human inter-
ventional studies comparing different durations of TTM
after cardiac arrest with return of spontaneous circula-
tion (ROSC). Enrolment of patients began 16 February
2013, and the last of the 355 patients was included 1
June 2016. The complete six-month outcome data will
be accessible in December 2016. The study protocol was
published previously [1]. According to good clinical
practice, and in order to prevent outcome reporting bias
and data-driven analyses, it is recommended to prepare
and publish a statistical analysis protocol (SAP) for the
main trial before any data analyses are initiated [2, 3].
Thus, our detailed SAP was formulated while data were
still being collected, and it was approved by the trial
steering committee.
Methods
Trial overview
The TTH48 trial is an investigator-initiated, inter-
national, multicentre, outcome assessor-blinded, parallel
group, pragmatic, randomised controlled trial (RCT)
comparing TTM at 33 (+/-1) °C for 24 and 48 hours in
OHCA patients.
The aim of TTH48 is to compare the effects of pro-
longed (48 hours) and standard duration (24 hours) of
TTM at 33 (±1) °C (TTM33) in comatose OHCA
patients. Our hypothesis is that 48 hours of TTM results
in better neurological outcomes (primary outcome) and
lower mortality (secondary outcome) without an in-
crease in adverse effects. In line with previous TTM
studies, the primary outcome is defined as the Cerebral
Performance Category (CPC) score at six months after
cardiac arrest, at this time the recovery potential follow-
ing OHCA induced cerebral injury is fully exploited.
The study comprises adult comatose patients with re-
turn of spontaneous circulation (ROSC) suffering from
OHCA. The published trial protocol (version 6.3) [1] is
available online at http://www.tth48.com In total, ten in-
tensive care units (Aarhus, Helsinki, Aalborg, Tallinn,
Stavanger, Brussels, Berlin, Copenhagen, Odense and
Turku) in six Northern European countries participated
in the study. The last trial patient was randomised on 1
June 2016. The protocol was prepared according to the
current version of the Helsinki Declaration (2013) and
approved by the local and regional research ethics com-
mittees listed in the appendix.
Aim
To prepare a detailed statistical analyses protocol for the
TTH48 trial.
We will also predetermine covariates, adjust analyses
and select subgroups for analysis, and use the OHCA
score, a validated score for predicting poor outcomes
after OHCA [4, 5].
Outcome
Primary outcome
The primary outcome is the CPC score at six months
after cardiac arrest. As in the previous TTM trials, good
neurological outcomes are defined as CPC scores of 1 or
2, and poor neurologic outcomes are defined as CPC
scores of 3, 4 or 5 (death).
Secondary outcomes and adverse events
The secondary outcomes are as follows: 1) mortality
within six months after cardiac arrest, 2) CPC score at
hospital discharge, 3) Glasgow Coma Scale (GCS) score
on day 4 after cardiac arrest, 4) adverse event(s), regis-
tered on day 4 and at discharge from hospital and de-
fined as the occurrence of one or more events such as
cerebral, circulatory, respiratory, gastrointestinal, renal,
metabolic measures, infection or bleeding, 5) progres-
sion of GCS from days 1 to 7 in the ICU, 6) GCS score
at ICU discharge and hospital discharge and 7) CPC
score at 30 and 90 days after cardiac arrest. A complete
list of adverse events is presented in the previously
published protocol paper [1].
Power analyses and randomisation
From a clinical point of view we considered an absolute
difference of 15% between the treatment groups to be
relevant. For sample size calculation an equation for
comparing two rates was used. A centre effect was not
taken into account. To detect a 15% absolute difference
in good outcomes (CPC score of 1 or 2) between the
two groups (two-sided) with 80% study power and a 5%
significance level (alpha), 169 patients were randomly
assigned each group (n = 338). To compensate for losses
between follow-ups and withdrawals of consent, the
sample size was increased by 5% (17 patients) forming
a study population of 355 patients. The web-based
clinical trials management system ”TrialPartner” was
used for randomization and data collection. Patients
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were assigned (1:1) to the treatment regimens by block
randomisation using randomly permuted block sizes of
6,4 and 2 - stratified in terms of trial centre, age (above
and below 60 years) and initial rhythm (shockable or non-
shockable). TrialPartner permits, with a personal log-in,
24 hour randomization. All actions in the system are
logged. The investigators did not know the block sizes.
Inclusion of patients was stopped on 1 June 2016, result-
ing in the inclusion of 355 patients.
Variables
We pre-defined variables for adjusted analyses of the
primary and secondary outcomes for all trial patients
and the pre-defined subgroups. The predefined covari-
ates are as follows: trial site, age, gender, initial cardiac
rhythm, time to ROSC and bystander cardiopulmonary
resuscitation (CPR). In addition, the analyses will be
adjusted with any additional baseline variable revealing
a significant difference between the treatment (TTM)
groups. The pre-defined subgroups are based on the
following criteria: age (below or above 60 years), first
presenting cardiac rhythm (shockable or not sho-
ckable), time to ROSC (longer or shorter than 25
minutes [6]), bystander CPR (performed or not per-
formed), methods of TTM (invasive or non-invasive),
time to target temperature from ROSC (longer or
shorter than 240 minutes [7]), OHCA score (more or
less than 20 points) [4, 5] and study site (the site with
the highest number of recruited patients compared to
the other sites).
Baseline variables
1. Gender
2. Age
3. Comorbidity
a. According to the APACHE II score definition [8]
i. Liver cirrhosis
ii. Chronic heart failure (New York Heart
Association [NYHA] Classification 4)
iii. Chronic obstructive, restrictive or vascular
pulmonary disease (treated by medication)
iv. Chronic dialysis
v. Immuno-compromised state
b. Diabetes mellitus (treated with medication)
c. Previous acute myocardial infarction (AMI)
d. Previous percutaneous coronary intervention
(PCI) or coronary artery bypass grafting (CABG)
e. Previous cardiac arrest
f. Previous stroke
g. Pre-morbid CPC
4. Pre-hospital variables
a. Location of cardiac arrest
i. Home
ii. Public place
iii. Other
b. Witness of arrest by
i. Civilian
ii. Emergency medical service (EMS)
iii. None or unknown
c. Bystander CPR
i. No
ii. Yes
1. With automated external defibrillator
(AED)
2. Without AED
d. Shockable rhythm at EMS arrival
i. Yes
ii. No or unknown
e. Use of mechanical compression device
i. Yes
ii. No or unknown
f. Time from cardiac arrest to start of basic life
support (no flow time)
g. Time from cardiac arrest to start of advanced
life support
h. Time from cardiac arrest to return of
spontaneous circulation (ROSC) (no flow time
plus total time of basic and advanced life support
[low flow time])
5. Time from ROSC to start of TTM
6. Time from ROSC to randomisation
7. Time from ROSC to target temperature (34 °C)
8. 8.TTM method
a. Non-invasive
b. Invasive (intravenous TTM catheter)
c. Cold intravenous fluids
9. Data on ICU admission
a. First measured core temperature
b. First measured blood pressure (mean arterial
pressure)
c. First measured pulse rate
d. First measured arterial PO2
e. First measured arterial PCO2
f. First measured arterial pH
g. First measured lactate
h. First measured serum creatinine
i. Acute ST-elevation infarction or new left bundle
branch block (LBBB)
Intervention period variables
Core temperature was measured in the bladder or
oesophagus and reported each hour during the interven-
tion period until 72 hours after the target temperature
was achieved. The target temperature is defined as the
time at which a core temperature of ≤ 34 °C is reached
in the ICU. Time 0 (T0) is defined as the time when the
target temperature is reached.
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Cardiovascular examinations and interventions
The number of patients during the first 72 hours of the
study receiving coronary angiography (CAG) or percu-
taneous coronary intervention (PCI) will be reported.
The number of patients receiving mechanical assist
devices, including intra-aortic balloon pumps (IABPs);
echocardiography; coronary bypass grafting; temporary
pacemakers or implantable cardioverter devices (ICDs)
will also be reported.
Neurological examinations and interventions
The number of patients that undergo electro encep-
halograms (EEGs), somatosensory evoked potential tests
(SSEPs), magnetic resonance imaging (MRI) and/or com-
puted tomography of the cerebrum (CTC) during their
initial ICU course will be reported. Further, the number of
patients with diagnosed brain death and/or withdrawal of
care due to a cerebral reason other than brain death will
be reported.
Other descriptive variables
The number of days in the ICU, days on mechanical
ventilation (time to extubation) during index ICU ad-
mission and days in the primary hospital during index
admission will be reported.
Cause of death
Patients that die during the hospital stay will have
their cause of death classified as one of the follow-
ing: cardiac failure, multiple organ dysfunction, brain
death or withdrawal of active treatment because of a
cerebral condition other than brain death or another
reason.
General principles for the statistical analyses
The general principles of the analyses are as follows:
1) Analyses will be conducted according to the
modified intention to treat (ITT) principle [9] if not
otherwise stated.
2) Risks will be reported as hazard ratios (HR) or odds
ratios (ORs) with a 95% confidence interval (CI).
3) All statistical tests will be two-sided with a significance
level of 5%. Continuous variables will be summarised
using mean +/- standard deviation (SD) for data with
normal distribution and median with interquartile
range points (25th and 75th) in parenthesis, for
non-normally distributed data.
4) Missing values will not be imputed [10, 11]. The
primary trial outcome will be tested in unadjusted
analyses, and we do not foresee many missing values
in these analyses.
5) Fisher’s exact test or the χ2 test will be used to
compare binary or categorical data.
6) Continuous data will be tested for normality and
compared between intervention groups using the
Student t-test or Wilcoxon rank sum test according
to the data distribution.
7) Unadjusted analyses and analyses adjusted for
pre-defined covariates will be carried out for each
primary and secondary outcome variables and for
each sub-group [12]. Other analyses may be
performed on different populations, such as
per-protocol treated patients. The results of these
additional analyses will be considered suitable for
generating hypotheses only.
8) Logistic regression models will be used for
multivariable analyses, and the results will be
reported as ORs with 95% CI.
9) Cox regression analyses and a Kaplan Meier plot will
be used for time-to-event analyses. Results will be
given as hazard ratios (HRs) with 95% CI.
10) When blocks of many statistical tests are
performed, the number of statistically significant
results will be compared with the expected number
of false significances due to statistical type I errors.
Statistical analyses
Trial profile
A CONSORT [13] diagram (Fig. 1) will display the flow of
adult OHCA patients admitted to the ICU. The number
of patients that did not meet inclusion criteria and the
number of patients, excluded before and after randomisa-
tion, with reasons for exclusion will be reported.
Primary outcome
The primary outcome is CPC score at six months after
cardiac arrest. CPC scores of 1 and 2 indicate good
neurological outcomes and scores of 3, 4 or 5 indicate
poor neurological outcomes. The statistical null hypoth-
esis is that there is no difference in primary outcomes
between 24 and 48 hours of TTM. This will be tested in
the modified ITT population by applying Fisher’s exact
(or chi-square) test to a 2 × 2 contingency table.
The primary trial outcome will be reported as an
unadjusted ratio with 95% CI and an absolute risk differ-
ence with 95% CI. Any significant difference in the num-
ber of patients needed to treat (NNT) for benefit or
harm (with 95% CI) will be reported.
The second analysis of the primary outcome data,
adjusted for the predetermined baseline covariates, will
include all randomised patients who received the inter-
vention and did not withdraw their consent according to
the modified ITT principle [7, 10].
The third analysis of the primary outcome, adjusted
for the predetermined baseline covariates, will include
randomised patients who did not violate any major
protocols (per-protocol analysis).
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The fourth analysis of the primary outcome data will
be adjusted for pre-specified covariates and any signifi-
cant imbalance in baseline covariates (P < 0.05).
The fifth analysis will be a sensitivity analysis of pre-
defined sub-groups (as described earlier).
All of these analyses will use logistic regression
models. The goodness-of-fit of the logistic regression
models will be assessed by graphical diagnostics and the
Hosmer-Lemeshow test. The results will be reported as
ORs with 95% CI.
Secondary outcomes
Mortality
A time-to-event analysis will be performed for mortality (up
to six months after cardiac arrest) using Kaplan-Meier curves,
log-rank tests, unadjusted and adjusted Cox proportional
hazard regression models and hazard ratios with 95% CI.
Adverse events
The number of patients that experience one or more ad-
verse events and the number of patients that experience
no adverse events will be compared using Fisher’s exact
(or chi-square) test. If there is a significant difference
between the treatment groups in terms of the occur-
rence of adverse events, we will try to identify the event
that is responsible for the difference. Prolonged TTM
may increase the risk of infection and, as it affects co-
agulation, the frequency of pneumonia and any bleeding
in the two treatment groups will be compared using
Fisher’s exact test. The definitions of pneumonia and
bleeding are presented in the protocol paper [1].
GCS and CPC
GCS scores will be reported as the median and range and
compared between the two treatment groups with a non-
parametric test. CPC scores will be compared between the
groups using logistic regression and following the modi-
fied ITT principle, as with the primary outcome data.
Baseline variables
The baseline characteristics listed above will be presented
in a table presenting the treatment groups. Discrete
Fig. 1 TTH48 CONSORT Flow Diagram
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variables will be summarised according to frequencies and
percentages. Percentages will be calculated according to
the number of patients for which data are available. When
values are missing, the actual denominators will be stated.
Intervention period variables
One hour means of temperature in the two intervention
groups will be displayed in a graph summarised according
to distribution as mean +/- 2 SD
Temperatures from the target temperature (T0) until 24
hours of TTM will be compared using a repeated mea-
sures analysis of variance (ANOVA). The time from
ROSC to achievement of the target temperature will be
compared between the two groups using a parametric or
nonparametric test according to the data distribution.
Temperatures measured during the rewarming period
will be compared between the two groups using a re-
peated measures ANOVA. The temperature change
during the first four hours after rewarming to 37 °C will
be compared between the two groups. The area under
the temperature curve and the peak temperature will be
calculated and compared using parametric or nonpara-
metric statistics according to the data distribution. The
time from the end of TTM (24 or 48 hours) to a
temperature of 37 °C will be compared between the
groups. The temperatures measured at 60 and 72 hours
will also be compared between the two groups.
Neurological, cardiovascular and other outcome data
Data will be presented in a table divided by treatment
group. Discrete variables will be summarised according
to frequencies and percentages. Percentages will be
calculated according to the number of patients for which
data are available. When values are missing, the actual
denominators will be stated.
Patients in the 48 hour group will, according to the
intervention, be sedated and placed on a ventilator 24
hours longer than the 24 hour group. This may, how-
ever, be balanced by the potential positive effect of
prolonged TTM. In order to elucidate this interaction,
the length of stay in the ICU, days on mechanical venti-
lation (time to extubation) and hospital length of stay
(LOS) will be compared between groups. The data will
be tested for normality and compared with Student’s t-
test or a non-parametric test according to the data
distribution.
Data monitoring, interim analyses and safety
The trial has been monitored by the Data Monitoring
and Safety Committee (DMSC), an independent com-
mittee that aims to safeguard the interests of trial partic-
ipants, assess the safety and efficacy of interventions
during the trial and monitor the overall conduct of the
clinical trial. Two interim analyses were performed. The
first was based on adverse events that occurred during
the intervention performed on the first 175 patients, and
the second was based on six-month CPC analyses of the
same 175 patients. The DMSC used P < 0.001 (Haybittle-
Peto) and group sequential monitoring boundaries as
statistical limits to guide its recommendations regarding
early termination of the trial. The DMSC recommended
that the TTH48 trial should continue as planned follow-
ing two data safety analyses (20 December 2015 and 27
February 2016). Tests for futility were not performed.
Data monitoring will be performed at each site by the
principal investigator (PI) or a person appointed by the
PI. The PI’s unit will be monitored by a member of the
steering committee located outside of the PI’s centre. It
will be ensured that all enrolled patients signed consent
forms as per local ethical practice. A randomly chosen
portion of trial patients (20%) will be checked for appro-
priate inclusion and exclusion criteria. The complete
data of a randomly chosen sample (5%) of the included
patients will be reviewed at each site.
When the final data have been registered, the trial
database will be locked. Afterwards, the planned statis-
tical analyses will be performed by a statistician using
blinded binary indicators for the two treatment groups.
The results will then be incorporated in the final report
by the writing group before the data are un-blinded.
Hans Kirkegaard (the study’s PI) and Asger Pedersen
(the study’s statistician) will take responsibility for ensur-
ing the integrity of the data. The study data will be made
available to the journal to which the study is submitted.
Figures and tables
Figure 1 will be a CONSORT flow chart. Figure 2 will be
a temperature graph for the two groups with hours on
the x-axis (-4 to 80, with 0 as the time at which the
patients in each group reached a temperature of 34 °C in
the ICU) and temperature on the y-axis. Figure 3 will be
a Kaplan-Meier plot presenting the mortality rate during
the six-month follow-up period. Figure 4 will be a forest
plot of the effects of intervention on the pre-defined
sub-groups. Table 1 will present baseline variables. Table
2 will present adverse events. Table 3 will present GSC
and CPC scores, with the number of patients in each
category of CPC reported separately but not compared.
Table 4 will present the cardiovascular and neurological
examinations and interventions, Table 5 will present
patients’ ICU and in-hospital LOS and time to extuba-
tion and Table 6 will present the course of death of
patients that died in the hospital.
Conclusion
In order to avoid the risk of outcome reporting bias and
data-driven analyses, the present paper reports a pre-
defined detailed SAP for the TTH48 trial. The TTH48 trial
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aims to increase current knowledge regarding the optimal
length of TTM and reduce the number of knowledge gaps
referred to in the recommendations in the recent Consen-
sus on Science and Treatment publication [14], one of
which concerns the effect of the length of TTM.
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